imbb logo for mobile
 
Angeliki Magklara

Angeliki Magklara

Αssistant Professor of Clinical Chemistry, Department of Medicine, School of Health Sciences, University of Ioannina
Email address
This email address is being protected from spambots. You need JavaScript enabled to view it.
  
This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone
+30 26510 07818, +30 2811392161
Fax
+30 2651 007077

Angeliki Magklara is an Assistant Professor of Clinical Chemistry at the Department of Medicine, School of Health Sciences, University of Ioannina. She received her Bachelor's degree from the Department of Biology and her Master's on Clinical Biochemistry from the Department of Chemistry at the National Kapodistrian University of Athens. Having developed an interest in cancer biology, she moved to the Department of Laboratory Medicine and Pathobiology at the University of Toronto, Canada, where she worked for her PhD thesis on the characterization of new members of the human kallikrein gene family and their evaluation as potential new tumor biomarkers (supervisor Dr. E.P. Diamandis). Later on, she joined, for her post-doctoral training, the Laboratory of Receptor Biology and Gene Expression at the National Institutes of Health (NCI/NIH) in Bethesda, Maryland, USA, where she worked on mechanisms of action of the progesterone receptor in breast cancer (supervisor Dr. C.L. Smith). Her newly developed research interests in epigenetics and her wish to obtain experience working with animal models led her to the University of California in San Francisco (UCSF), where she worked at Dr. S. Lomvardas' laboratory. There, she studied mechanisms of epigenetic regulation of the olfactory receptor genes in mice. In 2010 she was elected Lecturer of Clinical Chemistry at the University of Ioannina. In 2012 she was awarded a Marie Curie Career Integration Grant and she moved back to Greece, where she joined the Biomedical Research Department of IMBB at Ioannina. In January 2014, she assumed her academic position. Her current research interests lie in the field of cancer epigenetics and cancer stem cells.

Lyons DB,  Magklara A, Goh T, Sampath S, Schaefer A, Schotta G, Lomvardas S. (2014) Heterochromatin-Mediated Gene Silencing Facilitates the Diversification of Olfactory Neurons. Cell 9:1-9

Kougioumtzi A, Tsaparas P, Magklara A. (2014) Deep sequencing reveals new aspects of progesterone receptor signaling in breast cancer cells. PLoS One 9:e98404.

Magklara A, Lomvardas S. (2013) Stochastic gene expression in mammals: Lessons from Olfaction. Trends in Cell Biology 23:449-56.

Clowney EJ, Magklara A, Colquitt BM, Pathak N, Lane RP, Lomvardas S. (2011) High-throughput mapping of the promoters of the mouse olfactory receptor genes reveals a new type of mammalian promoter and provides insight into olfactory receptor gene regulation. Genome Res. 21:1249-59.

Magklara A, Yen A, Colquitt BM, Clowney EJ, Allen W, Markenscoff-Papadimitriou E, Evans ZA, Kheradpour P, Mountoufaris G, Carey C, Barnea G, Kellis M, Lomvardas S. (2011) An epigenetic signature for monoallelic olfactory receptor expression. Cell 145:555-70.

1.        Le Gros MA, Clowney EJ, Magklara A, Yen A, Markenscoff-Papadimitriou E, Colquitt B, Myllys M, Kellis M, Lomvardas S, Larabell CA. Soft X-Ray Tomography Reveals Gradual Chromatin Compaction and Reorganization during Neurogenesis In Vivo.  Cell Rep. 2016 Nov 15;17(8):2125-2136.

2.        Magklara A, Evangelopoulos DS, Nicolopoulos K, Chrousos G, Darviri C.  Stress management programs in chronic low back pain: Randomized controlled trial. ARCHIVES OF HELLENIC MEDICINE   2015 Sept-Nov; 32(5): 583-591.

3.         Verigos J and Magklara A. Revealing the Complexity of Breast Cancer by Next Generation Sequencing. Cancers (Basel) 2015;7(4):2183-200. 

4.        Lyons DB, Magklara A, Goh T,Sampath S,Schaefer A,Schotta G, Lomvardas S. Heterochromatin-Mediated Gene Silencing Facilitates the Diversification of Olfactory Neurons. Cell Rep.2014;9:1-9.

5.        Kougioumtzi A, Tsaparas P, Magklara A. Deep sequencing reveals new aspects of progesterone receptor signaling in breast cancer cells.PLoS One. 2014 Jun 4;9(6):e98404.

6.         Magklara A and Lomvardas S: Stochastic gene expression in mammals: Lessons from Olfaction. Trends in Cell Biology 2013 Sep;23(9):449-56.

7.         Johnson MA, Tsai L, Roy DS, Valenzuela DH, Mosley C, Magklara A, Lomvardas S, Liberles SD, Barnea G. Neurons expressing trace amine-associated receptors project to discrete glomeruli and constitute an olfactory subsystem. Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):13410-5.

8.         Clowney EJ, Magklara A, Colquitt BM, Pathak N, Lane RP, Lomvardas S. High-throughput mapping of the promoters of the mouse olfactory receptor genes reveals a new type of mammalian promoter and provides insight into olfactory receptor gene regulation. Genome Res. 2011 Aug;21(8):1249-59

9.         Magklara A, Yen A, Colquitt BM, Clowney EJ, Allen W, Markenscoff-Papadimitriou E, Evans ZA, Kheradpour P, Mountoufaris G, Carey C, Barnea G, Kellis M, Lomvardas S. An epigenetic signature for monoallelic olfactory receptor expression.Cell. 2011 May 13;145(4):555-70.

10.         Lee SC, Magklara A, Smith CL. HDAC activity is required for efficient core promoter function at the mouse mammary tumor virus promoter. J Biomed Biotechnol. 2011;2011:416905

11.         Magklara A, Smith CL. A composite intronic element directs dynamic binding of the progesterone receptor and GATA-2. Mol Endocrinol. 2009;23:61-73.

12.         YousefGM,  ObiezuCV, LuoLY, MagklaraA, BorgoñoCA, KishiK, MemariN,  MichaelIP, SidiropoulosM, KurlenderL, EconomopoulouK, KapadiaC, KomatsuN, PetrakiC, ElliottM, ScorilasA, KatsarosD, Levesque1 MA, DiamandisEP. Human Tissue Kallikreins: From Gene Structure to Function and Clinical Applications. Adv Clin Chem 2005;39:11-79

13.     Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Ghosh M, Wasney G, Diamandis EP. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression.J Biol Chem. 2005;280:14628-35.

14.     Sauter ER, Lininger J, Magklara A, Hewett JE, Diamandis EP. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. Int J Cancer. 2004;108:588-91.

15.     Kapadia C, Yousef GM, Mellati AA, Magklara A, Wasney GA, Diamandis EP. Complex formation between human kallikrein 13 and serum protease inhibitors. Clin Chim Acta 2004;339:157-67.

16.     Magklara A, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, Becker GW, Diamandis EP. Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun. 2003;307:948-55.

17.     Yousef GM, Scorilas A, Magklara A, Memari N, Ponzone R, Sismondi P, Abd Ellatif M, and Diamandis EP. The androgen regulated gene human kallikrein 15 (KLK15) is an independent and favorable prognostic marker for breast cancer. Br J Cancer 2002;87:1294-300.

18.     Sauter ER, Welch T, Magklara A, Klein G, Diamandis EP. Ethnic variation in kallikrein  expression in nipple aspirate fluid. Int J Cancer.  2002;100:678-82.

19.     Magklara A, Brown TJ and Diamandis EP. Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. Int J Cancer.2002;100: 507-14.

20.     Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Danese S, Diamandis EP. The human KLK8 (neuropsin/ovasin) gene: Identification of two novel slice variants and its prognostic value in ovarian cancer. Clin Cancer Res. 2001;7:806-11.

21.     Scorilas A, Magklara A, Hoffman BR, Bromberg RM, Bjartell A and Diamandis EP. Highly sensitive array analysis using time resolved fluorescence and a novel streptavidin-based reagent. Analytical Sciences 2001;17(suppl):i547-i551.

22.     Yousef GM,Magklara A and Diamandis EP.Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies Cancer Res. 2001;61:3425-31.

23.     Obiezu CV, Scorilas A, Magklara A, Thornton MH, Wang CY, Stanczyk FZ, Diamandis EP. Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome.J Clin Endocrinol Metab 2001;86:1558-61.

24.     Diamandis EP, Yousef GM, Luo LY, Magklara A and Obiezu CV. The new human kallikrein gene family-implications in carcinogenesis. Trend Endocrinol Metab 2000;11:54-60.

25.     Yousef GM, Magklara A and DiamandisEP.KLK12 is a novel serine protease and a new member of the human kallikrein gene family- Differential expression in breast cancer. Genomics, 2000;69:331-41.

26.     Yousef GM, Scorilas A, Magklara A, Soosaipillai A, Diamandis EP. The PRSS6 gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family-genomic characterization, mapping, tissue expression and hormonal regulation. Gene, 2000;254:119-128.

27.     Magklara A, Scorilas A, Stephan C, Kristiansen GO, Hauptmann S, Jung K and Diamandis EP. Decreased concentrations of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) in malignant vs non-malignant prostatic tissue. Urology, 2000;56:527-32.

28.     Magklara A, Cheung CC, Asa SL, Diamandis EP. Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland. Clinica Chimica Acta, 2000;300:171-80.

29.     Obiezu CV, Giltay EJ, Magklara A, Scorilas A, Gooren L, Yu H, Diamandis EP. Dramatic suppression of plasma and urinary prostate specific antigen and human glandular kallikrein by antiandrogens in male-to-female transsexuals. J Urol2000;163:802-5.

30.     Obiezu CV, Giltay EJ, Magklara A, Scorilas A, Gooren L, Yu H, Howarth DJC and Diamandis EP. Serum and urinary prostate specific antigen and urinary human glandular kallikrein concentration are significantly elevated after testosterone administration in female to male transsexuals. Clinical Chemistry 2000;46:859-862.

31.     Zand Rosenberg RS, Grass L, Magklara A, Jenkins DJA and Diamandis EP. Is ICI 182-780 an anti-progestin in addition to being an anti-estrogen? Breast Cancer Res Treat 2000;60:1-8.

32.     Magklara A, Grass L, Diamandis EP. Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate specific antigen (PSA) in breast cancer cell lines. Breast Cancer Res Treat 2000;59:263-70.

33.     Nam RK, Diamandis EP, Toi A, Trachtenberg J, Magklara A, Scorilas A, Papanastasiou PA, Jewett MAS and Narod SA. Serum human glandular kallikrein (hK2) protease levels predict the presence of prostate cancer among men with elevated prostate specific-antigen. Journal of Clinical Oncology 2000;18:1036-42.

34.     Black MH, Magklara A, Obiezu CV, Levesque MA, Sutherland DJA, Tindall DJ, Young CYF, Sauter ER, Diamandis EP. Expression of a prostate associated protein, human glandular kallikrein (hK2) in breast tumors and in normal breast secretions. Br J Cancer 2000;82:361-7.

35.     Magklara A, Scorilas A, Catalona WJ, Diamandis EP. The combination of human glandular kallikrein (hK2) and free PSA enhances the discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately elevated total PSA levels. Clinical Chemistry 1999;45:1960-6.

36.     Magklara A, Scorilas A, López-Otín C, DiamandisEP. Human glandular kallikrein (hK2) in breast milk, amniotic fluid and breast cyst fluid. Clinical Chemistry, 1999;45:1774-80.

37.     Black MH, Magklara A, Obiezu CV, Melegos DN, Diamandis EP. Development of an ultrasensitive immunoassay for human glandular kallikrein (hK2) with no cross reactivity from prostate specific antigen (PSA). Clinical Chemistry 1999;45:790-9.